会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Online data fusion
    • 在线数据融合
    • US09348891B2
    • 2016-05-24
    • US13311034
    • 2011-12-05
    • Divesh SrivastavaXin DongXuan Liu
    • Divesh SrivastavaXin DongXuan Liu
    • G06F17/30
    • G06F17/30634
    • An online data fusion system receives a query, probes a first source for an answer to the query, returns the answer from the first source, refreshes the answer while probing an additional source, and applies fusion techniques on data associated with an answer that is retrieved from the additional source. For each retrieved answer, the online data fusion system computes the probability that the answer is correct and stops retrieving data for the answer after gaining enough confidence that data retrieved from the unprocessed sources are unlikely to change the answer. The online data fusion system returns correct answers and terminates probing additional sources in an expeditious manner without sacrificing the quality of the answers.
    • 在线数据融合系统接收查询,探索第一个来源以获得查询的答案,从第一个源返回答案,在探索附加的源时刷新答案,并对与检索到的答案相关联的数据应用融合技术 从额外的来源。 对于每个检索到的答案,在线数据融合系统计算出答案正确的概率,并且在获得足够的信心从而从未处理的源中检索的数据不太可能改变答案之后,停止检索答案数据。 在线数据融合系统返回正确的答案,并以迅速的方式终止探测附加来源,而不牺牲答案的质量。
    • 5. 发明授权
    • Systems and methods for performing scoring optimization
    • 执行评分优化的系统和方法
    • US08762260B2
    • 2014-06-24
    • US13585218
    • 2012-08-14
    • Xiao HongXiaolan SongXin DongHuchen FeiLihua Wang
    • Xiao HongXiaolan SongXin DongHuchen FeiLihua Wang
    • G06Q40/02
    • G06Q40/025G06Q40/00G06Q40/02
    • The invention provides systems and methods relating to generating a unified determination based on subdetermination, and in particular, generating a unified score based on respective scores. For example, the invention provides a method for generating a unified determination based on subdeterminations, the method including generating a first subdetermination based on first criteria; generating a second subdetermination based on second criteria; and generating a unified determination based on the first subdetermination and the second subdetermination. The generation of the unified determination includes (a) assigning, using iterative processing, an assigned weighting respectively to the first determination and second determination; (b) determining if the assigned weighting satisfies at least one constraint; (c) comparing the assigned weighting to an optimized weighting, which was previously determined, to determine if the assigned weighting is improved over the optimized weighting; and (d) if the assigned weighting is improved, then assigning the assigned weighting to be the optimized weighting.
    • 本发明提供了关于基于子确定生成统一确定的系统和方法,并且特别地,基于各个分数生成统一的分数。 例如,本发明提供一种用于基于子确定来生成统一确定的方法,所述方法包括基于第一准则生成第一子确定; 基于第二准则生成第二子确定; 并且基于第一子确定和第二子确定生成统一的确定。 统一确定的生成包括(a)分别使用迭代处理分配的加权分配给第一确定和第二确定; (b)确定所分配的加权是否满足至少一个约束; (c)将所分配的权重与先前确定的优化加权进行比较,以确定所分配的权重是否比所述优化加权得到改善; 和(d)如果分配的权重得到改善,则将所分配的加权分配为优化加权。
    • 7. 发明授权
    • Analogs of ghrelin substituted at the N-terminal
    • 在N-末端取代的生长素释放肽的类似物
    • US08299022B2
    • 2012-10-30
    • US12311409
    • 2007-09-24
    • Zheng Xin Dong
    • Zheng Xin Dong
    • A61K38/22A61K38/27A61K38/16C07K14/00C07K14/61
    • C07K14/60A61K38/00
    • The invention comprises peptidyl analogs of ghrelin having greater stability which are active at the GHS receptor according to formulae depicted below: (R2)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-R1 wherein the definitions of A1 to A28, R1 and R2 are provided for in the specification, with the exception that the N-terminal amino acid must be selected from the group consisting of Inp, 1-Apc and 4-Apc, the pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of said compound together with therapeutic and non-therapeutic uses thereof.
    • 本发明包括具有更高稳定性的生长素释放肽的肽基类似物,其在GHS受体下具有活性,如下所示:(R2)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 -A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-R1其中A1至A28,R1和R2的定义用于 规格,除了N-末端氨基酸必须选自Inp,1-Apc和4-Apc,其药学上可接受的盐和药物组合物包含有效量的所述化合物以及治疗和非 - 其治疗用途。
    • 8. 发明申请
    • Pharmaceutical Compositions of Melanocortin Receptor Ligands
    • 黑皮质素受体配体的药物组合物
    • US20120225816A1
    • 2012-09-06
    • US13508777
    • 2010-11-15
    • Zheng Xin DongJundong Zhang
    • Zheng Xin DongJundong Zhang
    • A61K38/12A61P5/00
    • A61K38/33A61K9/0019A61K9/0024A61K9/08A61K38/34C07K14/68C07K14/69
    • The present invention relates to improvements in compositions containing peptides that are ligands of one or more of the melanocortin receptors (MC-R), or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and method of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of Ac-Arg-cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 which is a ligand of the melanocortin receptor subtype 4 (MC4-R), and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms a depot at physiological pH that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol (PEG) with an average molecular weight of lower than 1000.
    • 本发明涉及包含作为一种或多种黑皮质素受体(MC-R)或其药学上可接受的盐的配体的肽的组合物的改进,以及用于制备该组合物的方法以及使用这些组合物治疗哺乳动物的方法。 特别地,本发明涉及包含作为黑皮质素受体配体的Ac-Arg-环(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH 2的双羟萘酸盐的药物组合物 亚型4(MC4-R),并且其中在对受试者皮下或肌肉内施用后,肽在生理pH下形成缓慢溶解并释放到体液和血流中的贮库。 本发明还可以包含平均分子量低于1000的有机组分如二甲基乙酰胺(DMA)或聚乙二醇(PEG)。